JP2024543147A5 - - Google Patents
Info
- Publication number
- JP2024543147A5 JP2024543147A5 JP2024531227A JP2024531227A JP2024543147A5 JP 2024543147 A5 JP2024543147 A5 JP 2024543147A5 JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024531227 A JP2024531227 A JP 2024531227A JP 2024543147 A5 JP2024543147 A5 JP 2024543147A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical product
- product according
- seq
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/JP2021/043459 WO2023095305A1 (en) | 2021-11-26 | 2021-11-26 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
| JPPCT/JP2021/043459 | 2021-11-26 | ||
| PCT/JP2022/039605 WO2023095510A1 (en) | 2021-11-26 | 2022-10-25 | Treatment of a demyelinating disease of the central nervous system (cns) with satralizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543147A JP2024543147A (ja) | 2024-11-19 |
| JP2024543147A5 true JP2024543147A5 (https=) | 2025-10-30 |
Family
ID=86539186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024531227A Pending JP2024543147A (ja) | 2021-11-26 | 2022-10-25 | 中枢神経系（ｃｎｓ）の脱髄疾患のサトラリズマブによる治療 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250034265A1 (https=) |
| JP (1) | JP2024543147A (https=) |
| KR (1) | KR20240107372A (https=) |
| CN (1) | CN118591389A (https=) |
| AU (1) | AU2022398430A1 (https=) |
| CA (1) | CA3238940A1 (https=) |
| IL (1) | IL313058A (https=) |
| MX (1) | MX2024006393A (https=) |
| TW (1) | TW202330030A (https=) |
| WO (3) | WO2023095305A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761637B (zh) | 2006-03-31 | 2021-10-15 | 中外制药株式会社 | 调控抗体血液动力学的方法 |
| ES2595638T3 (es) | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| WO2018203545A1 (ja) | 2017-05-02 | 2018-11-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| WO2019151418A1 (ja) | 2018-01-31 | 2019-08-08 | 元一 加藤 | Ｉｌ－６阻害剤を含有する喘息の治療剤 |
| EP3957324A4 (en) | 2019-04-17 | 2023-02-08 | Hiroshima University | THERAPEUTIC FOR UROLOGICAL ONCOLOGY CHARACTERIZED BY BEING ADMINISTRATED IN COMBINATION WITH IL-6 INHIBITOR AND CCR2 INHIBITOR |
| EP4159236A4 (en) | 2020-05-29 | 2024-08-21 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing formulation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2010003329A (es) | 2007-09-26 | 2010-04-27 | Chugai Pharmaceutical Co Ltd | Anticuerpo anti-receptor de il-6. |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2010065116A2 (en) | 2008-12-02 | 2010-06-10 | The Trustees Of The University Of Pennsylvania | The use of il-27-p28 to antagonize il-6 mediated signaling |
| CA2972393A1 (en) | 2015-02-27 | 2016-09-01 | Chugai Seiyaku Kabushiki Kaisha | Composition for treating il-6-related diseases |
-
2021
- 2021-11-26 WO PCT/JP2021/043459 patent/WO2023095305A1/en not_active Ceased
-
2022
- 2022-10-25 MX MX2024006393A patent/MX2024006393A/es unknown
- 2022-10-25 KR KR1020247021082A patent/KR20240107372A/ko active Pending
- 2022-10-25 WO PCT/JP2022/039605 patent/WO2023095510A1/en not_active Ceased
- 2022-10-25 AU AU2022398430A patent/AU2022398430A1/en active Pending
- 2022-10-25 JP JP2024531227A patent/JP2024543147A/ja active Pending
- 2022-10-25 CA CA3238940A patent/CA3238940A1/en active Pending
- 2022-10-25 TW TW111140385A patent/TW202330030A/zh unknown
- 2022-11-25 IL IL313058A patent/IL313058A/en unknown
- 2022-11-25 US US18/712,917 patent/US20250034265A1/en active Pending
- 2022-11-25 CN CN202280089989.0A patent/CN118591389A/zh active Pending
- 2022-11-25 WO PCT/JP2022/043437 patent/WO2023095852A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024543147A5 (https=) | ||
| Bruijstens et al. | EU paediatric MOG consortium consensus: Part 5–Treatment of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders | |
| CN114173816A (zh) | 通过施用il-4r拮抗剂治疗特应性皮炎的方法 | |
| JP2024511970A5 (https=) | ||
| JP2023551559A5 (https=) | ||
| van der Meché et al. | The current place of high‐dose immunoglobulins in the treatment of neuromuscular disorders | |
| Marzano et al. | Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab) | |
| JP2021515039A5 (https=) | ||
| JP2025512785A5 (https=) | ||
| TWI870592B (zh) | 使用免疫檢查點抑制劑抗體治療癌症之方法和組合 | |
| RU2011117293A (ru) | Композиция для лечения заболевания | |
| JP2023545084A5 (https=) | ||
| JP2024521105A5 (https=) | ||
| Graves et al. | Immunotherapies in neurologic disorders | |
| JP2023546504A5 (https=) | ||
| Tenembaum | Therapy of multiple sclerosis in children and adolescents | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| Wolf et al. | Drug safety in thyroid eye disease–a systematic review | |
| CN119894516A (zh) | 用于治疗晚期实体瘤的组合物和方法 | |
| JP2023551519A5 (https=) | ||
| AU2019237774B2 (en) | Anti-VEGFR-2 antibody | |
| JP2025526402A5 (https=) | ||
| JP2024518410A5 (https=) | ||
| Alvi et al. | Post COVID anti-NMDAR encephalitis in an adolescent girl | |
| Khim | Myasthenia gravis treatment |